Reduced Content of Gluten Diet on Patients With Irritable Bowel Syndrome (Pro.Ali.Fun.) (PROALIFUN)
Primary Purpose
Irritable Bowel Syndrome, Gluten Sensitivity
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Reduced gluten bread and Pasta compared o normal gluten bread and Pasta
Sponsored by
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome
Eligibility Criteria
Inclusion Criteria:
- age above 18 years;
- having bowel symptoms (altered bowel habit, lower abdominal pain, bloating, or distention suggestive of IBS), as determined by Rome III criteria.
- Previous exclusion of CD and wheat allergy
Exclusion Criteria:
- previous GI malignancy and/or surgery;
- clinically significant cardiovascular, respiratory, endocrine, renal, hematologic or hepatic disease.
- other clinically significant medical condition; pregnancy or lactation; alcohol abuse; drug addiction; severe neurologic or psychiatric disorders; long-term use of corticosteroids or anti-inflammatory drugs
participation in another clinical trial within 6 months before the onset of this trial.
-
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Reduced Gluten-Normal Gluten
Normal Gluten-Reduced Gluten
Arm Description
Outcomes
Primary Outcome Measures
Change in Severity of IBS symptoms measured by Irritable Bowel Syndrome-Severity Score (IBS-SS)
Change in IBS Severity Score (IBS-SS) between reduced gluten content diet and standard gluten content diet. Mild, moderate and severe cases were indicated by scores of 75 to 175, 175 to 300 and "300 respectively. Mild, moderate and severe cases are indicated by scores of 75 to 175, 175 to 300, and >300, respectively.
Change of IBS severity measured by Visual analogue scale (VAS)
Change of severity of IBS symptoms measured by Visual analogue scale (VAS) between reduced gluten content diet and standard gluten content diet. The 0-10 mm VAS scale (0 no pain, 10 worst possible pain) included a horizontal color gradient (green-red).
Secondary Outcome Measures
Change of Quality of life scores
Irritable Bowel Syndrome Quality of Life (IBS-QoL) between reduced gluten content diet and standard gluten content diet.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03638544
Brief Title
Reduced Content of Gluten Diet on Patients With Irritable Bowel Syndrome (Pro.Ali.Fun.)
Acronym
PROALIFUN
Official Title
Effect of Wheat Bread and Pasta With Reduced Content of Gluten on Patients With Irritable Bowel Syndrome: Randomized Controlled Cross Over Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
January 1, 2014 (Actual)
Primary Completion Date
December 31, 2016 (Actual)
Study Completion Date
December 31, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Bari
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aim to manufacture bread and pasta with an reduced content of gluten and to assess the impact of reducing the daily intake of gluten by 50% in irritable bowel syndrome (IBS) patients. Fungal proteases and selected sourdough lactic acid bacteria will be used for making wheat bread and pasta with a reduced content of gluten (RG) (-50% of traditional products). From a technological point of view, the chemical, structural and sensory features of the RG products approached those of the bread and pasta made with normal level of gluten. The efficacy and safety of new products will be compared to traditional bread and pasta by using a double blind randomized, crossover-controlled trial in IBS patients with persistent gastrointestinal symptoms. Patients will follow two weeks of a GFD diet containing RG bread and pasta and two weeks of GFD diet containing Normal Gluten bread and pasta Symptoms severity will be assessed by Irritable Bowel Syndrome Severity Score (IBS-SS), Visual Analogue Scale (VAS), Hospital Anxiety and Depression Scale (HADS) and Irritable Bowel Syndrome Quality of Life (IBS-QoL).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome, Gluten Sensitivity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Double blind placebo controlled Gluten Sensitivity
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Reduced Gluten-Normal Gluten
Arm Type
Active Comparator
Arm Title
Normal Gluten-Reduced Gluten
Arm Type
Active Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Reduced gluten bread and Pasta compared o normal gluten bread and Pasta
Intervention Description
Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
Primary Outcome Measure Information:
Title
Change in Severity of IBS symptoms measured by Irritable Bowel Syndrome-Severity Score (IBS-SS)
Description
Change in IBS Severity Score (IBS-SS) between reduced gluten content diet and standard gluten content diet. Mild, moderate and severe cases were indicated by scores of 75 to 175, 175 to 300 and "300 respectively. Mild, moderate and severe cases are indicated by scores of 75 to 175, 175 to 300, and >300, respectively.
Time Frame
two weeks of each different diet interspersed by one week of wash out. The questionnaire will be completed ones a week.
Title
Change of IBS severity measured by Visual analogue scale (VAS)
Description
Change of severity of IBS symptoms measured by Visual analogue scale (VAS) between reduced gluten content diet and standard gluten content diet. The 0-10 mm VAS scale (0 no pain, 10 worst possible pain) included a horizontal color gradient (green-red).
Time Frame
Two weeks of each different diet interspersed by one week of wash out. The scale will be completed ones a day.
Secondary Outcome Measure Information:
Title
Change of Quality of life scores
Description
Irritable Bowel Syndrome Quality of Life (IBS-QoL) between reduced gluten content diet and standard gluten content diet.
Time Frame
two weeks of each different diet interspersed by one week of wash out. The scale will be completed ones a week.
10. Eligibility
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age above 18 years;
having bowel symptoms (altered bowel habit, lower abdominal pain, bloating, or distention suggestive of IBS), as determined by Rome III criteria.
Previous exclusion of CD and wheat allergy
Exclusion Criteria:
previous GI malignancy and/or surgery;
clinically significant cardiovascular, respiratory, endocrine, renal, hematologic or hepatic disease.
other clinically significant medical condition; pregnancy or lactation; alcohol abuse; drug addiction; severe neurologic or psychiatric disorders; long-term use of corticosteroids or anti-inflammatory drugs
participation in another clinical trial within 6 months before the onset of this trial.
-
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Reduced Content of Gluten Diet on Patients With Irritable Bowel Syndrome (Pro.Ali.Fun.)
We'll reach out to this number within 24 hrs